Global Tissue Engineered Skin Substitute Market was valued US$ xx Bn. in 2019 and the total revenue is expected to grow at 13.5% through 2019 to 2027, reaching US$ xx Bn.
The report has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis. Tissue engineering is a technique used to improve, maintain, and restore damaged organs & tissues. It grows functional tissues as a substitute to natural ones by a grouping of scaffolds, physically active cells and molecules. The skin substitute is developed by using non-human tissue or human tissue, or a combination of both. The technique is usually used in the treatment of burns, chronic wounds and acute wounds. The market for tissue-engineered skin substitute is expected to grow significantly in forecast period because of the rise in the incidence of other skin diseases like burn injuries. Researchers are focusing on establishing new construction technologies in the arena of skin tissue engineering, which is likely to offer an opportunity for the major growth in tissue-engineered skin substitute market. The 3-D bio textile and bio printing have emerged as dominant tools in the tissue-engineered skin substitute market globally. Growing prevalence of diabetes is estimated to boost the market. This is because the risk of emerging diabetic foot ulcer in diabetic patients. As per the WHO report, the incidence of diabetes for all age-groups was projected to be 2.8 % in 2000 & estimated to increase to 4.4 % in 2030. The total number of people with diabetes is expected to rise from 171 Mn. in 2000 to 366 Mn. in 2030. Therefore, the prevalence of diabetes, related complications is likely to upsurge the demand for tissue engineered skin substitute over 2019-2027. The report covers the segments in the tissue engineered skin substitute markets by product, application, and end-use. By product, the biological segment was valued US$ xx Mn. in 2019 and is expected to reach US$ xx Mn. by 2027 at a CAGR of 33% over the forecast period. This is attributed to the growing prevalence of acute wounds across the world. The major benefit of biological tissue engineered skin substitutes is that skin is easily available from the patient. North America is expected to continue to dominate the market with XX% share in global tissue engineered skin substitute market because of the growing incidence of chronic wounds. People with diabetes require effective and proper therapeutics, and henceforth the demand for incretin-based drugs is witnessing a significant upsurge across the USA. In Canada, the prevalence of diabetes amongst adults is 10.2% and nearby 3.6 Mn. patients were suffering from diabetes in 2017. Some patients suffering from type-2 diabetes is 94.5 % of the diabetic population. It drives the demand for tissue engineered market of region. The competitive landscape section in the tissue engineered skin substitute market offers a deep dive into the profiles of the leading companies operating in the global market landscape. It offers captivating insights on the key developments, differential strategies, and other crucial aspects about the key players having a stronghold in the tissue engineered skin substitute market. The objective of the report is to present a comprehensive analysis of the Global Tissue Engineered Skin Substitute Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market has been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding Global Tissue Engineered Skin Substitute Market dynamics, structure by analyzing the market segments and projects the Global Tissue Engineered Skin Substitute Market size. Clear representation of competitive analysis of key players by Application, price, financial position, Product portfolio, growth strategies, and regional presence in the Global Tissue Engineered Skin Substitute Market make the report investor’s guide.
Scope of the Global Tissue Engineered Skin Substitute Market
Global Tissue Engineered Skin Substitute Market, by Product
• Synthetic • Biosynthetic • Biological
Global Tissue Engineered Skin Substitute Market, by Application
• Acute Wounds o Surgery & Trauma o Burn Injuries • Chronic Wounds o Diabetic Foot Ulcers o Pressure Ulcers o Venous Leg Ulcers o Other Chronic Wounds
Global Tissue Engineered Skin Substitute Market, by End-Use
• Hospitals • Wound Care Centers • Others
Global Tissue Engineered Skin Substitute Market, by Region
• North America • Europe • Asia-Pacific • South America • Middle East & Africa
Key players operating in the Global Tissue Engineered Skin Substitute Market
• Smith & Nephew • Mölnlycke Health Care AB • Integra LifeSciences Corporation • Regenicin. • Organogenesis Inc • MiMedx. • LifeNet Health • Kerecis • Medline Industries, Inc • BSN medical • ConvaTec Group PLC • Mallinckrodt • Tissue Regenix • AMARANTUS BIOSCIENCE HOLDINGS, INC. • Stratatech Corporation